# Label Schema

The standardized format for each nation / region is described below. We utilize this to generate the label data XML/CSV files. 

## UK/EU drug label sections
Summary of Product Characteristics (SmPC) - [description](https://www.ema.europa.eu/en/documents/presentation/presentation-summary-product-characteristics_en.pdf)

----

- 1. Name of the Medicinal Product
- 2. Qualiatative and Quantitative Composition
- 3. Pharmaceutical Form
- 4. Clinical Particulars
    - 4.1 Therapeutic Indications
    - 4.2 Posology and Method of Administration
    - 4.3 Contraindications
    - 4.4 Special Warnings and Precautions for Use
    - 4.5 Interactions with Other Medicinal Products and Other Forms of Interaction
    - 4.6 Fertility, Pregnancy, and Lactation
    - 4.7 Effects on Ability to Drive and Use Machines
    - 4.8 Undesirable Effects
    - 4.9 Overdose
- 5. Pharmacological Properties
    - 5.1 Pharmacodynamic Properties
    - 5.2 Pharmacokinetic Properties
    - 5.3 Preclinical Safety Data
- 6. Pharmaceutical Particulars
    - 6.1 List of Excipients
    - 6.2 Incompatibilities
    - 6.3 Shelf Life
    - 6.4 Special Precautions for Storage
    - 6.5 Nature and Contents of Container
    - 6.6 Special Precautions for Disposal and Handling of Product
- 7. Marketing Authorization Holder
- 8. Marketing authorisation number(s)
- 9. Date of first authorisation/renewal of the authorisation
- 10. Date of revision of the text

## JP Drug Label Sections 
- 医療用医薬品の添付文書 - [description](https://www.pmda.go.jp/files/000229049.pdf)
- NOTE : The translations listed are our descriptions for ease of comparing sections between JP and other drug labels that we have adapted from translation guidance provided by the PMDA. We do make best effort to ensure their accuracy but they are not official, and official documentation provided by the [PMDA](https://www.pmda.go.jp/english/) should be referenced. 
---

- ア. 作成又は改訂年月 (Date Document Produced / Revised)
- イ. 日本標準商品分類番号 (Standard Commodity Classification Number of Japan)
- ウ. 承認番号、販売開始年月 (Approval Number, ☆Date of Initial Marketing in Japan)
- エ. 貯法、有効期間 (Storage, Shelf Life)
- オ. 薬効分類名 (Therapeutic Category)
- カ. 規制区分 (Regulatory Classification)
- キ. 名称 (Name of Medicinal Product)

- 1. 警告 (Warnings)
- 2. 禁忌（次の患者には投与しないこと）(Contraindications)
- 3. 組成・性状 (Composition and Product Description)
    - 3.1 組成 (Composition)
    - 3.2 製剤の性状 (Product Description)
- 4. 効能又は効果 (Indications)
- 5. 効能又は効果に関連する注意 (Precautions Concerning Indications)
- 6. 用法及び用量 (Dosage and Administration)
- 7. 用法及び用量に関連する注意 (Precautions Concerning Dosage and Administration)
- 8. 重要な基本的注意 (Important Precautions)
- 9. 特定の背景を有する患者に関する注意 (Precautions Concerning Patients With Specific Background)
    - 9.1 合併症・既往歴等のある患者 (Patients with Complication or History of Disease)
    - 9.2 腎機能障害患者 (Patients with Renal Impairment)
    - 9.3 肝機能障害患者 (Patients with Hepatic Impairment)
    - 9.4 生殖能を有する者 (Patients with Reproductive Potential)
    - 9.5 妊婦 (Pregnant Women)
    - 9.6 授乳婦 (Breastfeeding Women)
    - 9.7 小児等 (Pediatric Use)
    - 9.8 高齢者 (Geriatric Use)
- 10. 相互作用 (Interactions with Other Medicinal Products)
    - 10.1 併用禁忌（併用しないこと）(Contraindications for Co-administration)
    - 10.2 併用注意（併用に注意すること）(Precautions for Co-administration)
- 11. 副作用 (Adverse Reactions)
    - 11.1 重大な副作用 (Clinically Significant Adverse Reactions)
    - 11.2 その他の副作用 (Other Adverse Reactions)
- 12. 臨床検査結果に及ぼす影響 (Influence on Laboratory Tests)
- 13. 過量投与 (Overdose)
- 14. 適用上の注意 (Precautions Concerning Use)
- 15. その他の注意 (Other Precautions)
    - 15.1 臨床使用に基づく情報 (Information Based on Clinical Use)
    - 15.2 非臨床試験に基づく情報 (Information Based on Nonclinical Studies)
- 16. 薬物動態 (Pharmacokinetics)
    - 16.1 血中濃度 (Blood Level)
    - 16.2 吸収 (Absorption)
    - 16.3 分布 (Distribution)
    - 16.4 代謝 (Metabolism)
    - 16.5 排泄 (Excretion)
    - 16.6 特定の背景を有する患者 (Patients with Specific Backgrounds)
    - 16.7 薬物相互作用 (Drug-Drug Interactions)
    - 16.8 その他 (Other)
- 17. 臨床成績 (Clinical Studies)
    - 17.1 有効性及び安全性に関する試験 (Clinical Studies for Efficacy and Safety)
    - 17.2 製造販売後調査等 (Post-Marketing Surveillance etc.)
    - 17.3 その他 (Other)
- 18. 薬効薬理 (Pharmacology)
    - 18.1 作用機序 (Mechanism of Action)
- 19. 有効成分に関する理化学的知見 (Physicochemical Properties)
- 20. 取扱い上の注意 (Handling Precautions)
- 21. 承認条件 (Approval Conditions)
- 22. 包装 (Packaging)
- 23. 主要文献 (References)
- 24. 文献請求先及び問い合わせ先 (Reference Requests and Contact Information)
- 25. 保険給付上の注意 (Precautions Concering Health Insurance Benefits)
- 26. 製造販売業者等 (Marketing Authorization Holder)